title: Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
authors.forename: Antonio
authors.initials: A
authors.lastname: Jiménez-Velasco
authors.forename: Manuel
authors.initials: M
authors.lastname: Barrios
authors.forename: Magdalena
authors.initials: M
authors.lastname: Alcalá
authors.forename: Ana Isabel
authors.initials: AI
authors.lastname: Heiniger
mesh_terms: D001549:Benzamides; D006287:Health Planning Guidelines; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010677:Philadelphia Chromosome / Q000187:drug effects*; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases